Vaccibody ipo. Mar 31, 2021 · If an emerging growth company, indicate by check mark ...

Vaccibody ipo. Mar 31, 2021 · If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act. Jul 10, 2020 · Listing Vaccibody AS on Euronext Growth Oslo. Vaccibody’s front runner program (VB10. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big Pharma partner with deep pockets — and with it, a new name and facelift. He was the founding CEO of PsiOxus Therapeutics, where he advanced multiple clinical programs, secured major strategic partnerships, raised substantial capital, and built an IPO-ready organization. Regeneron is betting nearly $1 billion on five new vaccine programs from Vaccibody, now called Nykode Therapeutics. Prior to founding Vaccibody, Dr. Nov 24, 2021 · Norwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable deal with Regeneron to develop vaccines for cancer and infectious diseases The Nykode Therapeutics platform is built around the Vaccibody molecule: An immunotherapy platform for the future of medicine. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). rpbgf vsh hcznz omr zvzuih gmh rgstur ifjk lyvjmo ejeuu